reports
Phillips Edison & Company Announces Pricing of Offering of $350 Millio...
Phillips Edison & Company Announces Pricing of Offering of $350 Million Aggregate Principal Amount of 5.750% Senior Unsecured Notes Due 2034 CINCINNATI, May 08, 2024 (GLOBE NEWSWIRE) -- Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of the nation’s largest owners and operators of grocery-anchored neighborhood shopping centers, today announced that its operating partnership, Phillips Edison Grocery Center Operating Partnership I, L.P. (the “Operating Partnership”), has priced a public offering of $350 million aggregate principal amount of 5.750% senior unsecu...
SiTime Reports First Quarter 2024 Financial Results
SiTime Reports First Quarter 2024 Financial Results SANTA CLARA, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- SiTime Corporation, (Nasdaq: SITM), the Precision Timing company, today announced financial results for the first quarter ended March 31, 2024. Net revenue in the first quarter of 2024 was $33.0 million, a 22% decrease from $42.4 million in the prior quarter. “SiTime is a leading provider of precision timing chips in electronics markets such as datacenter, AI and industrial,” said Rajesh Vashist, CEO and chairman of SiTime. “Our investments to expand our product portfolio, including...
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
Oculis Reports Q1 2024 Financial Results and Provides Company Updates ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED); RELIEF topline results anticipated in Q2 2024Completed $59 million registered direct equity offering and concurrent listing on Nasdaq Iceland Main Market in April 2024, extending cash runway into the second half of 2026Strengthened executive ...
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
Oculis Reports Q1 2024 Financial Results and Provides Company Updates Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED); RELIEF topline results anticipated in Q2 2024Completed $59 million registered direct equity offering and concurrent listing on Nasdaq Iceland Main Market in April 2024, extending cash runway into the second half of 2026Strengthened executive leadership team and U.S. presence with the appointmen...
CytomX Therapeutics Reports First Quarter 2024 Financial Results and P...
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY® ADC, in solid tumors. Initial data anticipated in the first half of 2025 - - Phase 1 study initiation activities continue for CX-801, an interferon alpha-2b PROBODY® cytokine, including the execution of a clinical collaboration agreement with Merck to supply KEYTRUDA® (pe...
Crescent Capital BDC, Inc. Reports First Quarter Net Investment Income...
Crescent Capital BDC, Inc. Reports First Quarter Net Investment Income Per Share of $0.63 and NAV Per Share of $20.28; Increases Quarterly Dividend LOS ANGELES, May 08, 2024 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (“Crescent BDC” or “Company”) (NASDAQ: CCAP) today reported net investment income of $0.63 per share and net income of $0.76 per share for the quarter ended March 31, 2024. Net asset value per share increased to $20.28 compared to $20.04 as of December 31, 2023. Dividend Declarations The Company increased its regular quarterly cash dividend by $0.01 to $0.42 per share....
Taboola to Present in Upcoming Investor Conferences
Taboola to Present in Upcoming Investor Conferences NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Taboola (Nasdaq: TBLA), a global leader in powering recommendations for the open web, today announced that members of its management team will participate in the following investor conferences: Event: Oppenheimer 9th Annual Emerging Growth ConferenceDate: Thursday, May 9, 2024 Event: 19th Annual Needham Technology, Media, & Consumer ConferenceDate: Wednesday, May 15, 2024 Presentation Time: 1:30 p.m. ET Event: J.P. Morgan 52nd Annual Global Technology, Media and Communications ConferenceDate:...
Profire Energy Reports Financial Results for First Quarter 2024
Profire Energy Reports Financial Results for First Quarter 2024 Company Reports Strong Performance on Revenue Diversification LINDON, Utah, May 08, 2024 (GLOBE NEWSWIRE) -- Profire Energy, Inc. (NASDAQ: PFIE), a technology company (the "Company") that provides solutions which enhance the efficiency, safety, and reliability of industrial combustion appliances, today reported financial results for its first quarter ending March 31, 2024. A conference call will be held on Thursday, May 9, 2024 at 8:30 a.m. ET to discuss the results. First Quarter Summary (comparisons to prior-year...
ContextLogic Inc. Reports First-Quarter 2024 Financial Results
ContextLogic Inc. Reports First-Quarter 2024 Financial Results OAKLAND, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: WISH) (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter ended March 31, 2024. Introductory Note Prior to the April 19, 2024 closing of the Asset Sale described below, ContextLogic owned and operated the Wish platform, a mobile ecommerce platform. As a result of the Asset Sale, ContextLogic no longer owns the Wish platform or any of the related operating assets. Since the Asset Sale was not complet...
Pharvaris Reports First Quarter 2024 Financial Results and Provides Bu...
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacksExecuting from a strong financial position with cash and cash equivalents of €368 million as of March 31, 2024 ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists t...
IGM Biosciences Announces First Quarter 2024 Financial Results and Pro...
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update - Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended March 31, 2024 and provided an update on recent developments. “W...
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalatio...
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager) - CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial signs of efficacy observed for CX-904 in advanced pancreatic cancer, including 2 of 6 patients (33%) with a confirmed partial response and all 6 patients (100%) with disease control - - Preliminary pharmacokinetic and pharmacodynamic analyses are supportive of PROB...
TEN Ltd. Announces the Filing of Form 20-F With the SEC
TEN Ltd. Announces the Filing of Form 20-F With the SEC ATHENS, Greece, May 08, 2024 (GLOBE NEWSWIRE) -- TEN, Ltd. (TEN) (NYSE: TNP) (the “Company”) announced today that its Annual Report on Form 20-F for the year ended December 31, 2023, has been filed with the U.S. Securities and Exchange Commission (“SEC”) and can be accessed on its website, Alternatively, shareholders may also receive a hard copy of the annual report, free of charge, by contacting us using the contact details provided at the end of this press release. ABOUT TSAKOS ENERGY NAVIGATION TEN, founded in 1993, is one of ...
Anika Announces CFO Transition
Anika Announces CFO Transition Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024 BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company’s Executive Vice President, Chief Financial Officer (“CFO”) and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a sm...
P10 Provides Corporate Governance Updates
P10 Provides Corporate Governance Updates Appoints Luke Sarsfield to Chairman, Effective in June Improves Governance Policy Through Termination of Stockholder Rights Plan DALLAS, May 08, 2024 (GLOBE NEWSWIRE) -- (NYSE: PX) (the “Company”), a leading private markets solutions provider, today announced several enhancements to its governance structure and policy. Robert Alpert informed the P10 Board of Directors (the “Board”) of his decision to step down as Executive Chairman, effective June 14, 2024, concurrent with the P10 Annual Meeting. Mr. Alpert will continue to s...
Lulus Announces Stock Repurchase Program
Lulus Announces Stock Repurchase Program CHICO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Lulu's Fashion Lounge Holdings, Inc. (“Lulus” or the “Company”) (Nasdaq: LVLU), the attainable luxury brand for women, today announced that its Board of Directors has authorized a stock repurchase program of up to $2.5 million of Lulus common stock. The stock repurchase program does not obligate the Company to acquire any particular amount of common stock, and it may be modified, extended or terminated by the Board of Directors at any time. “We are committed to strategically deploying capital to ge...
Context Therapeutics Reports First Quarter 2024 Operating and Financia...
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and reported on recent business highlights. “We believe Context has had a great start to 202...
Matrix Service Company Reports Third Quarter Fiscal 2024 Results
Matrix Service Company Reports Third Quarter Fiscal 2024 Results TULSA, Okla., May 08, 2024 (GLOBE NEWSWIRE) -- Matrix Service Company (Nasdaq: MTRX), a leading North American industrial engineering, construction, and maintenance contractor, today announced results for the third quarter fiscal 2024 ended March 31, 2024. THIRD QUARTER FISCAL 2024 RESULTS (all comparisons versus the prior year period unless otherwise noted) Total backlog of $1.45 billion, +74% on a year-over-year basis, the highest level in 40-year company historyTotal project awards of $186.8 million, resulting in a boo...
Cytek Biosciences Reports First Quarter 2024 Financial Results
Cytek Biosciences Reports First Quarter 2024 Financial Results FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Total revenue was $44.9 million, representing a 21% increase over the corresponding period of 2023 Organic revenue was $37.3 million, representing an increase of 11% compared to the first quarter of 2023First quarter revenue from the product lines acquired from Lumine...
Supernus Announces First Quarter 2024 Financial Results
Supernus Announces First Quarter 2024 Financial Results Net sales of Qelbree® increased 75% to $45.1 million compared to first quarter 2023.Total revenues were $143.6 million. Total revenues excluding Trokendi XR® and Oxtellar XR® net product sales (non-GAAP)(1) increased 12% to $100.7 million compared to first quarter 2023.Operating loss was $(3.2) million. Adjusted operating earnings (non-GAAP)(1) was $22.3 million.Reiterates full year 2024 financial guidance, including total revenue guidance of $580 million to $620 million, operating loss guidance of $(30) million to $0 million, and adju...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.